Vyome Holdings, Inc. (Vyome Therapeutics)

Vyome Holdings, Inc. is a clinical-stage healthcare company focused on developing therapeutic products for immuno-inflammatory and rare diseases. The company aims to address unmet medical needs by creating novel solutions that regulate the immuno-inflammatory response. Headquartered in Cambridge, Massachusetts, Vyome Holdings operates as a global healthcare platform that integrates biotechnology, medical devices, and artificial intelligence.

The company's pipeline includes several product candidates, such as VT-1953, a topical gel under development for malignant fungating wounds in cancer, and VT-1908, an immune modulator being repurposed for steroid-sparing anterior uveitis. Additionally, Vyome is developing VB1953 for moderate to severe acne. The company has also commercialized two reformulated topical anti-fungal products in India based on its Molecular Replacement Therapeutics (MRT) platform.

Vyome Holdings, Inc. became publicly traded on Nasdaq under the ticker symbol HIND in August 2025, following a transaction involving ReShape Lifesciences. Recent developments include the presentation of Phase 2 clinical study data for VT-1953 at AACR 2026 and the filing for Orphan Drug Status for the same candidate in early 2026. Venkat Nelabhotla serves as the CEO, leading the company's strategy to leverage the US-India innovation corridor for cost-efficient development and market access.